Phase 3 Asthma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing and able to provide written consent before any study procedures begin
• People who are Chinese, male or female, and between 18 and 75 years of age
• People who have a documented asthma diagnosis of at least 1 year, and whose asthma was first diagnosed before the age of 40
• People whose asthma is not well controlled and who have been taking a combination of two inhaled medications — a medium-dose inhaled corticosteroid (ICS) and a long-acting bronchodilator (LABA) — at a stable dose for at least 4 weeks before the screening visit
• People whose lung function test (measuring how much air can be exhaled) shows a result below 80% of the expected normal value, after stopping certain inhalers for a set period before the screening visit
• People whose lungs show a meaningful improvement in airflow after using a bronchodilator during the screening test
• People whose asthma symptoms score 1.5 or higher on a standard asthma control questionnaire (ACQ-7), measured at both the screening visit and at the point of being assigned to a treatment group

Who may not be able to join:

• People with a history of life-threatening asthma attacks, or past hospital admission for a very severe asthma episode, where the trial doctor judges this may pose an unacceptable risk
• People who have been hospitalised, visited an emergency room, or taken oral or injectable steroid medications for an asthma flare-up in the 4 weeks before screening or during the lead-in period
• People who have had any asthma flare-up or respiratory tract infection in the 4 weeks before screening or during the lead-in period
• People whose ICS and LABA combination medication had a change in dose, schedule, or formulation in the 4 weeks before screening
• People who have taken oral or injected steroid medications in the 4 weeks before screening, or slow-release steroid medications in the 12 weeks before screening
• People with a diagnosis of chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, alpha-1 antitrypsin deficiency, or any other significant lung condition that may affect the study results
• People who currently smoke, who are ex-smokers with a total smoking history of 10 pack-years or more, or who stopped smoking within 1 year before the screening visit
• People who are currently being treated with monoclonal antibody therapies or biological drugs (for example, anti-IgE or anti-IgG treatments)
• People who have taken an experimental drug within 2 months or six half-lives (whichever is longer) before screening, who have previously been enrolled in this study, or who are currently taking part in another clinical trial

Important: Always verify eligibility with the trial site directly before applying.